A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
Clarke JM, Blobe GC, Strickler JH, Uronis HE, Zafar SY, Morse M, Dropkin E, Howard L, O'Neill M, Rushing CN, Niedzwiecki D, Watson H, Bolch E, Arrowood C, Liu Y, Nixon AB, Hurwitz HI.
Clarke JM, et al. Among authors: liu y.
Cancer Chemother Pharmacol. 2019 Oct;84(4):909-917. doi: 10.1007/s00280-019-03916-0. Epub 2019 Aug 23.
Cancer Chemother Pharmacol. 2019.
PMID: 31444620
Free PMC article.
Clinical Trial.